Hiroshi Saeki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hiroshi Saeki has a total of 660 co-authors. Here are the top co-authors by number of shared publications:
Yoshihiko Maehara
Innovative Anticancer Strategy for Therapeutics and Diagnosis Group, Innovation Center for Medical Redox Navigation, Kyushu University
120 shared publications- Masaru Morita
Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan
71 shared publications - Eiji Oki
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
67 shared publications - Koji Ando
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
47 shared publications - Tetsuo Ikeda
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
41 shared publications - Eiji Oki
Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan
37 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from DNA Replication Stress Induced by Trifluridine Determines Tumor Cell Fate According to p53 Status
The list of antibodies used in this study.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from DNA Replication Stress Induced by Trifluridine Determines Tumor Cell Fate According to p53 Status
The list of antibodies used in this study.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity
IC50 concentration of FTD in siRNA-treated DLD1 cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity
IC50 concentration of FTD in siRNA-treated DLD1 cells.